JYNT Quote, Financials, Valuation and Earnings

CVS Health has a net margin of 7.09% compared to The Joint's net margin of 1.88%. The Joint's return on equity of -37.87% beat CVS Health's return on equity of 7%.

The Joint has a consensus price target of $16.38, signalling upside risk potential of 55.51%. On the other hand CVS Health has an analysts' consensus of $79.09 which suggests that it could grow by 16.56%. Given that The Joint has higher upside potential than CVS Health, analysts believe The Joint is more attractive than CVS Health.

The Joint has a beta of 1.541, which suggesting that the stock is 54.11% more volatile than S&P 500. In comparison CVS Health has a beta of 0.598, suggesting its less volatile than the S&P 500 by 40.158%.

The Joint has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVS Health offers a yield of 3.92% to investors and pays a quarterly dividend of $0.67 per share. The Joint pays -- of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Joint quarterly revenues are -$38.3M, which are smaller than CVS Health quarterly revenues of $94.6B. The Joint's net income of -$2.7M is lower than CVS Health's net income of $1.8B. Notably, The Joint's price-to-earnings ratio is -- while CVS Health's PE ratio is 16.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint is 3.07x versus 0.23x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Enhabit has a net margin of 7.09% compared to The Joint's net margin of -17.82%. The Joint's return on equity of -37.87% beat Enhabit's return on equity of -23.93%.

The Joint has a consensus price target of $16.38, signalling upside risk potential of 55.51%. On the other hand Enhabit has an analysts' consensus of $9.00 which suggests that it could fall by -7.12%. Given that The Joint has higher upside potential than Enhabit, analysts believe The Joint is more attractive than Enhabit.

The Joint has a beta of 1.541, which suggesting that the stock is 54.11% more volatile than S&P 500. In comparison Enhabit has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Joint has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enhabit offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint pays -- of its earnings as a dividend. Enhabit pays out -- of its earnings as a dividend.

The Joint quarterly revenues are -$38.3M, which are smaller than Enhabit quarterly revenues of $258.2M. The Joint's net income of -$2.7M is higher than Enhabit's net income of -$46M. Notably, The Joint's price-to-earnings ratio is -- while Enhabit's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint is 3.07x versus 0.47x for Enhabit. Usually stocks with elevated PS ratios are considered overvalued.

IQVIA Holdings has a net margin of 7.09% compared to The Joint's net margin of 6.5%. The Joint's return on equity of -37.87% beat IQVIA Holdings's return on equity of 20.79%.

The Joint has a consensus price target of $16.38, signalling upside risk potential of 55.51%. On the other hand IQVIA Holdings has an analysts' consensus of $200.72 which suggests that it could grow by 30.94%. Given that The Joint has higher upside potential than IQVIA Holdings, analysts believe The Joint is more attractive than IQVIA Holdings.

The Joint has a beta of 1.541, which suggesting that the stock is 54.11% more volatile than S&P 500. In comparison IQVIA Holdings has a beta of 1.344, suggesting its more volatile than the S&P 500 by 34.416%.

The Joint has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IQVIA Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint pays -- of its earnings as a dividend. IQVIA Holdings pays out -- of its earnings as a dividend.

The Joint quarterly revenues are -$38.3M, which are smaller than IQVIA Holdings quarterly revenues of $3.8B. The Joint's net income of -$2.7M is lower than IQVIA Holdings's net income of $249M. Notably, The Joint's price-to-earnings ratio is -- while IQVIA Holdings's PE ratio is 20.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint is 3.07x versus 1.80x for IQVIA Holdings. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 7.09% compared to The Joint's net margin of -55.94%. The Joint's return on equity of -37.87% beat SCWorx's return on equity of -80.46%.

The Joint has a consensus price target of $16.38, signalling upside risk potential of 55.51%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that The Joint has higher upside potential than SCWorx, analysts believe The Joint is more attractive than SCWorx.

The Joint has a beta of 1.541, which suggesting that the stock is 54.11% more volatile than S&P 500. In comparison SCWorx has a beta of 2.355, suggesting its more volatile than the S&P 500 by 135.489%.

The Joint has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Joint pays -- of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend.

The Joint quarterly revenues are -$38.3M, which are smaller than SCWorx quarterly revenues of $759.7K. The Joint's net income of -$2.7M is lower than SCWorx's net income of -$425K. Notably, The Joint's price-to-earnings ratio is -- while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Joint is 3.07x versus 0.27x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.